Cara licenses Enteris' Peptelligence to develop oral formulation of Korsuva
Executive Summary
Enteris BioPharma Inc. granted Cara Therapeutics Inc. a non-exclusive worldwide license (excluding Japan and South Korea) to its Peptelligence drug delivery technology to use in the development, manufacture, and commercialization of Cara's oral Korsuva (difelikefalin; CR845), a long-acting synthetic peptide peripheral kappa opioid receptor (KOR) agonist.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Macromolecule
-
Drug Delivery
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice